Albany Molecular Research, Inc. AMRI
At closeJun 28, 2019, 6:07 PM EDT
- Market cap
- 928.25M
- Revenue (ttm)
- 680.81M
- Profit margin
- -8.78%
- EPS (ttm)
- -1.42
- Shares out
- 42.70M
- P/E ratio
- -15.32
- Forward P/E
- 17.67
- Volume
- 531.22K
- Avg volume
- 749.72K
- Open
- 21.74
- Previous close
- 21.74
- Day's range
- 21.73 – 21.76
- 52-week range
- 13.01 – 22.17
- Beta
- 0.59
- Analysts
- Hold
- Price target
- 10.70 (-50.8%)
- Earnings date
- Aug 17, 2017
Key statistics
- Enterprise value
- 0
- PEG ratio
- 0.00
- Price / sales
- 1.36
- Price / book
- 2.86
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 43.10%
- Free cash flow
- -52.58M
- Total cash
- 42.23M
- Total debt
- 647.96M
- Return on equity
- -20.61%
- Short % of float
- 21.09%
- 50-day average
- 21.73
- 200-day average
- 19.09
Analyst view
Consensus: hold
- Strong buy0
- Buy0
- Hold3
- Sell0
- Strong sell0
Next earnings
Aug 17, 2017
Expected Aug 17, 2017. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 17, 2017 | Jun 1, 2017 | 0.23 | — | — | — |
| May 9, 2017 | Mar 1, 2017 | 0.12 | — | — | — |
| Feb 21, 2017 | Dec 1, 2016 | 0.48 | — | — | — |
| Nov 8, 2016 | Sep 1, 2016 | 0.13 | — | — | — |
| Aug 4, 2016 | Jun 1, 2016 | 0.33 | — | — | — |
| May 10, 2016 | Mar 1, 2016 | 0.21 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jun 7, 2017 | JP Morgan | down | — | Neutral |
| May 10, 2017 | Morgan Stanley | down | — | Equal-Weight |
| Oct 25, 2015 | First Analysis | up | — | Overweight |
| Dec 17, 2014 | First Analysis | init | — | Equal-Weight |
| Sep 8, 2014 | JP Morgan | init | — | Overweight |
| Apr 8, 2014 | Morgan Stanley | init | — | Overweight |
About Albany Molecular Research, Inc.
Albany Molecular Research, Inc., a contract research and manufacturing company, provides integrated drug discovery, development, and manufacturing services primarily in the United States, Europe, and Asia. The companys Discovery and Development Services segment offers services from target identification tools to investigational new drug enabling activities, such as diverse chemistry library design and synthesis, high throughput and high content screening, medicinal chemistry, and biology, as well as pharmacology, including drug metabolism and pharmacokinetics. It also provides analytical chemistry and testing services for drug discovery, and pharmaceutical development and manufacturing; and chemical development technologies to promote the solutions for route development from late lead optimization to commercial manufacturing. Its Active Pharmaceutical Ingredients segment offers chemical synthesis and manufacturing services in accordance with current good manufacturing practice (cGMP) regulations. The companys Drug Product segment provides integrated pharmaceutical drug development programs and services, including process research and development, pre-formulation and formulation development, and GLP bioanalytical and separation sciences; formulation development services for solid dosage, solution, suspension, topicals, and injectables; and cGMP contract manufacturing services in sterile syringe and vial filling using specialized technologies, including lyophilization. Its Fine Chemical segment provides lab to commercial scale synthesis of reagents, and various compounds to the pharmaceutical, agrochemical, detergent, and cosmetic industries. The company serves pharmaceutical and biotechnology companies; government research entities and non-profit organizations; and agriculture, fine chemicals, contract chemical manufacturing, medical devices, and flavoring and cosmetics businesses. The company was founded in 1991 and is headquartered in Albany, New York.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- amriglobal.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on AMRI — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BOYER MILTON | Officer | Disposition (Non Open Market) | Aug 30, 2017 | 0 |
| CONWAY CHRISTOPHER M. | Officer | Acquisition (Non Open Market) | Aug 30, 2017 | 0 |
| D AMBRA CONSTANCE M | Beneficial Owner (10% or more) | Sale | Nov 8, 2015 | 2,365,818 |
| D AMBRA THOMAS E | Director | Disposition (Non Open Market) | Aug 30, 2017 | 0 |
| D'AMBRA DAVID | Beneficial Owner (10% or more) | Ownership Statement | Dec 16, 2015 | 16,290 |
| DEMING DAVID H | Director | Disposition (Non Open Market) | Aug 30, 2017 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 8.57% | 3,684,743 | 79.63M | Jun 29, 2017 |
| American Capital Management, Inc. | 6.04% | 2,598,220 | 56.15M | Jun 29, 2017 |
| Deutsche Bank Aktiengesellschaft | 5.57% | 2,394,885 | 51.75M | Jun 29, 2017 |
| Vanguard Group, Inc. (The) | 3.63% | 1,561,105 | 33.74M | Jun 29, 2017 |
| Citigroup Inc. | 3.26% | 1,404,192 | 30.34M | Jun 29, 2017 |
| Dimensional Fund Advisors LP | 3.13% | 1,346,341 | 29.09M | Jun 29, 2017 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Core S&P Smallcap ETF | 2.21% | 951,041 | 18.88M | May 30, 2017 |
| Royce Opportunity Fund | 1.79% | 770,744 | 10.21M | Mar 30, 2017 |
| Vanguard Total Stock Market Index Fund | 1.35% | 581,308 | 7.70M | Mar 30, 2017 |
| iShares NASDAQ Biotechnology ETF | 1.29% | 554,244 | 11.00M | May 30, 2017 |
| iShares Russell 2000 ETF | 1.22% | 524,743 | 10.42M | May 30, 2017 |
| Walthausen Small Cap Value Fd | 1.20% | 516,785 | 9.30M | Jan 30, 2017 |